“We have developed the first known BTK SH2 domain inhibitor, and have shown preclinically that it was effective at reducing skin inflammation in a model of CSU and has exquisite target ...

In biochemical and primary human cellular assays, the company’s STAT6 SH2 domain inhibitor demonstrated highly selective, picomolar potency for inhibiting STAT6 activation driven by IL-4.

Recludix Pharma, Inc. May 07, 2025, 12:00 PM ET -- Bruton’s tyrosine kinase (BTK) SH2 inhibitor reduced skin inflammation in a clinically-relevant model of chronic spontaneous urticaria (CSU) ...

-- Bruton’s tyrosine kinase (BTK) SH2 inhibitor reduced skin inflammation in a clinically-relevant model of chronic spontaneous urticaria (CSU) ...